GlassScriptPhysician profile
Elizabeth Lucas
NPI 1346524154
$1,743.23
in general payments reported to CMS, 2019-2025
19 companies · $452 in 2025
The $452 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $44.93 · 2021: $192 · 2022: $338 · 2023: $284 · 2024: $316 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.11 |
| Education | $112.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $429.42 | 2021-2025 | |
| Lilly USA, LLC | $367.41 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $187.95 | 2022-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $184.24 | 2022-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $79.92 | 2019-2022 | |
| Astellas Pharma US INC | $65.99 | 2024 | |
| Vanda Pharmaceuticals INC. | $64.36 | 2025 | Fanapt, Hetlioz |
| Amgen INC. | $58.99 | 2019-2024 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $44.90 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.75 | 2020-2022 | |
| Pfizer INC. | $42.02 | 2021-2024 | |
| Mylan Specialty L.P. | $31.59 | 2021 | |
| Novartis Pharmaceuticals Corporation | $30.22 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.81 | 2022 | |
| Alkermes, INC. | $23.29 | 2024 | Vivitrol |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $19.88 | 2023 | Gattex |
| Vbi Vaccine (Delaware) INC. | $14.38 | 2023 | Prehevbrio |
| Horizon Therapeutics Plc | $12.55 | 2019 | |
| Amarin Pharma, INC. | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Lucas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.